Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Syndicate
Ardelyx files $250M mixed securities shelf  06:44
07/09/20
07/09
06:44
07/09/20
06:44
ARDX

Ardelyx

$7.05 /

+0.04 (+0.57%)

 
ShowHide Related Items >><<
ARDX Ardelyx
$7.05 /

+0.04 (+0.57%)

ARDX Ardelyx
$7.05 /

+0.04 (+0.57%)

04/09/20 Piper Sandler
Piper has 'meaningfully higher' conviction in Ardelyx after management calls
03/09/20 Piper Sandler
Ardelyx remains a top pick after 'quiet' Q4 at Piper Sandler
02/18/20 Jefferies
Ardelyx assumed with a Buy at Jefferies
02/12/20
Fly Intel: Top five analyst initiations
ARDX Ardelyx
$7.05 /

+0.04 (+0.57%)

  • 05
    Dec
ARDX Ardelyx
$7.05 /

+0.04 (+0.57%)

Over a week ago
Hot Stocks
Ardelyx submits NDA to FDA for tenapanor » 08:03
06/30/20
06/30
08:03
06/30/20
08:03
ARDX

Ardelyx

$6.58 /

+0.225 (+3.54%)

Ardelyx announced the…

Ardelyx announced the submission of a New Drug Application for tenapanor to the U.S. FDA for the control of serum phosphorus in adult patients with chronic kidney disease on dialysis. Based on standard FDA review timelines, the company expects to receive notification from the FDA on the acceptance of the filing for substantive review in late August.

ShowHide Related Items >><<
ARDX Ardelyx
$6.58 /

+0.225 (+3.54%)

ARDX Ardelyx
$6.58 /

+0.225 (+3.54%)

04/09/20 Piper Sandler
Piper has 'meaningfully higher' conviction in Ardelyx after management calls
03/09/20 Piper Sandler
Ardelyx remains a top pick after 'quiet' Q4 at Piper Sandler
02/18/20 Jefferies
Ardelyx assumed with a Buy at Jefferies
02/12/20
Fly Intel: Top five analyst initiations
ARDX Ardelyx
$6.58 /

+0.225 (+3.54%)

  • 05
    Dec
ARDX Ardelyx
$6.58 /

+0.225 (+3.54%)

On The Fly
Fly Insider: Epizyme,DraftKings among week's notable insider transactions » 12:39
06/29/20
06/29
12:39
06/29/20
12:39
AVGO

Broadcom

$309.64 /

+2.27 (+0.74%)

, SSSS

SuRo Capital

$9.01 /

+0.05 (+0.56%)

, AESE

Allied Esports Entertainment

$2.05 /

-0.06 (-2.84%)

, DKNG

DraftKings

$34.32 /

+0.91 (+2.72%)

, AMSWA

American Software

$15.54 /

+0.33 (+2.17%)

, CATM

Cardtronics

$23.76 /

+1.475 (+6.62%)

, RPTX

Repare Therapeutics

$32.40 /

-0.01 (-0.03%)

, EPZM

Epizyme

$16.50 /

+0.99 (+6.38%)

, ARDX

Ardelyx

$6.67 /

+0.315 (+4.96%)

, APLT

Applied Therapeutics

$34.96 /

-0.43 (-1.22%)

Welcome to "Fly Insider,"…

Open Full Text

ShowHide Related Items >><<
SSSS SuRo Capital
$9.01 /

+0.05 (+0.56%)

EPZM Epizyme
$16.50 /

+0.99 (+6.38%)

DKNG DraftKings
$34.32 /

+0.91 (+2.72%)

CATM Cardtronics
$23.76 /

+1.475 (+6.62%)

AVGO Broadcom
$309.64 /

+2.27 (+0.74%)

ARDX Ardelyx
$6.67 /

+0.315 (+4.96%)

APLT Applied Therapeutics
$34.96 /

-0.43 (-1.22%)

AESE Allied Esports Entertainment
$2.05 /

-0.06 (-2.84%)

AVGO Broadcom
$309.64 /

+2.27 (+0.74%)

06/26/20
Fly Intel: Top five analyst upgrades
06/26/20 Evercore ISI
Evercore upgrades Broadcom to Outperform, sees Apple sales driving upside
06/26/20 Evercore ISI
Broadcom upgraded to Outperform from In Line at Evercore ISI
06/22/20 Mizuho
Broadcom price target raised to $350 from $325 at Mizuho
SSSS SuRo Capital
$9.01 /

+0.05 (+0.56%)

AESE Allied Esports Entertainment
$2.05 /

-0.06 (-2.84%)

06/08/20 Alliance Global Partners
Alliance Global says Allied Esports refinancing eliminates near-term overhang
05/15/20 Stephens
Allied Esports Entertainment price target lowered to $4 from $5 at Stephens
05/06/20 Alliance Global Partners
Allied Esports Entertainment initiated with a Buy at Alliance Global Partners
12/18/19
Fly Intel: Top five analyst initiations
DKNG DraftKings
$34.32 /

+0.91 (+2.72%)

06/26/20
Fly Intel: Top five analyst initiations
06/25/20 Rosenblatt
DraftKings initiated with a Buy at Rosenblatt
06/24/20 Goldman Sachs
DraftKings price target raised to $34 from $32 at Goldman Sachs
06/22/20
Fly Intel: Top five analyst initiations
AMSWA American Software
$15.54 /

+0.33 (+2.17%)

06/15/20 B. Riley FBR
American Software price target raised to $22 from $19.50 at B. Riley FBR
02/21/20 B. Riley FBR
American Software upgraded to Buy from Neutral at B. Riley FBR
11/19/19 B. Riley FBR
American Software downgraded to Neutral from Buy at B. Riley FBR
08/29/19 B. Riley FBR
American Software upgraded to Buy from Neutral at B. Riley FBR
CATM Cardtronics
$23.76 /

+1.475 (+6.62%)

05/22/20
Fly Intel: Top five analyst initiations
05/22/20 SunTrust
Cardtronics price target raised to $35 from $29 at SunTrust
05/22/20 Gabelli
Cardtronics initiated with a Buy at Gabelli
04/21/20 DA Davidson
Cardtronics price target lowered to $40 from $51 at DA Davidson
RPTX Repare Therapeutics
$32.40 /

-0.01 (-0.03%)

EPZM Epizyme
$16.50 /

+0.99 (+6.38%)

06/19/20 Citi
Epizyme should be bought on any confusion over label, at Citi
06/18/20 Jefferies
Jefferies sees broad approval for Epizyme's Taz as 'fundamental positive'
06/02/20 Wedbush
Epizyme removed from Best Ideas List at Wedbush
04/01/20 Oppenheimer
Epizyme downgraded to Perform at Oppenheimer
ARDX Ardelyx
$6.67 /

+0.315 (+4.96%)

04/09/20 Piper Sandler
Piper has 'meaningfully higher' conviction in Ardelyx after management calls
03/09/20 Piper Sandler
Ardelyx remains a top pick after 'quiet' Q4 at Piper Sandler
02/18/20 Jefferies
Ardelyx assumed with a Buy at Jefferies
02/12/20
Fly Intel: Top five analyst initiations
APLT Applied Therapeutics
$34.96 /

-0.43 (-1.22%)

04/22/20
Fly Intel: Top five analyst initiations
04/22/20 Goldman Sachs
Applied Therapeutics initiated with a Buy at Goldman Sachs
02/27/20 Barclays
Applied Therapeutics initiated with an Overweight at Barclays
02/27/20 Barclays
Applied Therapeutics initiated with an Overweight at Barclays
EPZM Epizyme
$16.50 /

+0.99 (+6.38%)

DKNG DraftKings
$34.32 /

+0.91 (+2.72%)

CATM Cardtronics
$23.76 /

+1.475 (+6.62%)

AVGO Broadcom
$309.64 /

+2.27 (+0.74%)

ARDX Ardelyx
$6.67 /

+0.315 (+4.96%)

APLT Applied Therapeutics
$34.96 /

-0.43 (-1.22%)

AMSWA American Software
$15.54 /

+0.33 (+2.17%)

  • 19
    Jun
  • 19
    Jun
  • 24
    Jan
  • 05
    Dec
DKNG DraftKings
$34.32 /

+0.91 (+2.72%)

AVGO Broadcom
$309.64 /

+2.27 (+0.74%)

RPTX Repare Therapeutics
$32.40 /

-0.01 (-0.03%)

EPZM Epizyme
$16.50 /

+0.99 (+6.38%)

DKNG DraftKings
$34.32 /

+0.91 (+2.72%)

AVGO Broadcom
$309.64 /

+2.27 (+0.74%)

APLT Applied Therapeutics
$34.96 /

-0.43 (-1.22%)

DKNG DraftKings
$34.32 /

+0.91 (+2.72%)

AVGO Broadcom
$309.64 /

+2.27 (+0.74%)

Hot Stocks
Ardelyx reports 'positive' data from ongoing NORMALIZE study » 08:04
06/15/20
06/15
08:04
06/15/20
08:04
ARDX

Ardelyx

$6.58 /

+0.37 (+5.96%)

Ardelyx reported positive…

Ardelyx reported positive data from its ongoing NORMALIZE study, which is designed to evaluate the ability of tenapanor, as monotherapy or in combination with sevelamer, to achieve serum phosphorus levels in the normal range in patients with chronic kidney disease on dialysis. Tenapanor is an investigational, first-in-class, phosphate absorption inhibitor which, if approved, will provide a completely new approach for the control of serum phosphorus in patients with CKD on dialysis, blocking the absorption of phosphorus at the primary pathway of uptake. "These data from the NORMALIZE study are unprecedented in terms of the proportion of patients able to achieve serum phosphorus levels less than 4.6mg/dL with foundational use of tenapanor," said Stuart Sprague DO, FASN, chief of the Division of Nephrology and Hypertension at Northshore University Health System. "This represents an important advancement in the management of hyperphosphatemia for patients on dialysis. The ability of tenapanor to drive phosphorus levels closer to normal has the potential to completely change the hyperphosphatemia treatment paradigm." The NORMALIZE extension study allowed patients from PHREEDOM, the positive Phase 3 long-term monotherapy study, to continue therapy with tenapanor, and enabled those in the safety control arm receiving sevelamer, to transition to tenapanor. The planned second analysis demonstrated that the foundational use of tenapanor as monotherapy or in combination with sevelamer carbonate produces a significant phosphorus-lowering effect with a mean serum phosphorous reduction of 2.33 mg/dL, from a mean baseline phosphorus of 7.27 mg/dL at the beginning of the PHREEDOM trial to a mean of 4.94 mg/dL at the time of this analysis. Of the 171 patients in this interim analysis who completed up to 9 months of treatment in this extension study, up to 47.4% achieved a normal serum phosphorus level, and of those, the majority were on tenapanor alone or tenapanor with low dose sevelamer of less than or equal to3 sevelamer tablets per day. These data represent a 58% improvement in the rate of patients who achieve a normal serum phosphorus level, as compared to current treatment practice data as reported in the April 2020 Dialysis Outcomes Practice Patterns Study Practice Monitor. The DOPPS data demonstrate that, with current standard of care treatment of phosphate binders alone, only 30% of patients have serum phosphorous levels less than 4.6 mg/dL. The only adverse event reported in greater than5% of patients in NORMALIZE was diarrhea, with an incidence rate of 23.3%.

ShowHide Related Items >><<
ARDX Ardelyx
$6.58 /

+0.37 (+5.96%)

ARDX Ardelyx
$6.58 /

+0.37 (+5.96%)

04/09/20 Piper Sandler
Piper has 'meaningfully higher' conviction in Ardelyx after management calls
03/09/20 Piper Sandler
Ardelyx remains a top pick after 'quiet' Q4 at Piper Sandler
02/18/20 Jefferies
Ardelyx assumed with a Buy at Jefferies
02/12/20
Fly Intel: Top five analyst initiations
ARDX Ardelyx
$6.58 /

+0.37 (+5.96%)

Over a month ago
Hot Stocks
Ardelyx names Justin Renz as CFO » 16:03
06/08/20
06/08
16:03
06/08/20
16:03
ARDX

Ardelyx

$7.37 /

+0.445 (+6.43%)

Ardelyx announced the…

Ardelyx announced the appointment of Justin Renz to the position of CFO. Renz brings an extensive array of financial and operational experience to Ardelyx. He most recently served as the president and CFO of Correvio Pharma.

ShowHide Related Items >><<
ARDX Ardelyx
$7.37 /

+0.445 (+6.43%)

ARDX Ardelyx
$7.37 /

+0.445 (+6.43%)

04/09/20 Piper Sandler
Piper has 'meaningfully higher' conviction in Ardelyx after management calls
03/09/20 Piper Sandler
Ardelyx remains a top pick after 'quiet' Q4 at Piper Sandler
02/18/20 Jefferies
Ardelyx assumed with a Buy at Jefferies
02/12/20
Fly Intel: Top five analyst initiations
ARDX Ardelyx
$7.37 /

+0.445 (+6.43%)

Hot Stocks
Ardelyx appoints Susan Rodriguez Chief Commercial Officer » 16:02
05/18/20
05/18
16:02
05/18/20
16:02
ARDX

Ardelyx

$7.67 /

+0.27 (+3.65%)

Ardelyx announced the…

Ardelyx announced the appointment of Susan Rodriguez, an industry veteran with over 25 years of global pharmaceutical experience, as the company's first Chief Commercial Officer. Rodriguez will be responsible for leading the commercial organization, including launch planning and strategy, as well as alliance management and business development. Previously, Rodriguez served as the founding CEO of Tolmar Pharmaceuticals, a U.S. commercial entity of marketed products, that was later merged with sister companies where she served as president of the branded division.

ShowHide Related Items >><<
ARDX Ardelyx
$7.67 /

+0.27 (+3.65%)

ARDX Ardelyx
$7.67 /

+0.27 (+3.65%)

04/09/20 Piper Sandler
Piper has 'meaningfully higher' conviction in Ardelyx after management calls
03/09/20 Piper Sandler
Ardelyx remains a top pick after 'quiet' Q4 at Piper Sandler
02/18/20 Jefferies
Ardelyx assumed with a Buy at Jefferies
02/12/20
Fly Intel: Top five analyst initiations
ARDX Ardelyx
$7.67 /

+0.27 (+3.65%)

Earnings
Ardelyx reports Q1 EPS (25c), consensus (25c) » 16:39
05/07/20
05/07
16:39
05/07/20
16:39
ARDX

Ardelyx

$7.20 /

-0.005 (-0.07%)

Reports Q1 revenue $1.2M,…

Reports Q1 revenue $1.2M, consensus $550K. Mike Raab, CEO, stated, "We are fortunate that much of our clinical work has been completed, with minimal impact of the pandemic on our business, and we are on track to submit our NDA for tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis by mid-year. In preparation for potential approval in mid-2021, we are laying the foundation for launch with important pre-commercial activities underway."

ShowHide Related Items >><<
ARDX Ardelyx
$7.20 /

-0.005 (-0.07%)

04/09/20 Piper Sandler
Piper has 'meaningfully higher' conviction in Ardelyx after management calls
03/09/20 Piper Sandler
Ardelyx remains a top pick after 'quiet' Q4 at Piper Sandler
02/18/20 Jefferies
Ardelyx assumed with a Buy at Jefferies
02/12/20
Fly Intel: Top five analyst initiations
Hot Stocks
Knight Therapeutics announces approval of IBSRELA in Canada » 07:39
04/17/20
04/17
07:39
04/17/20
07:39
ARDX

Ardelyx

$6.87 /

+0.19 (+2.84%)

Knight Therapeutics…

Knight Therapeutics announced that Health Canada has approved IBSRELA for the treatment of irritable bowel syndrome with constipation in adults. Knight and Ardelyx signed an agreement in March 2018 granting Knight the exclusive right to distribute IBSRELA in Canada for IBS-C and hyperphosphatemia. IBSRELA is a minimally-absorbed small molecule that acts locally in the gastrointestinal tract to inhibit the sodium-hydrogen exchanger NHE3, resulting in an increase in bowel movements and a decrease in abdominal pain for IBS-C patients. On September 12, 2019, the U.S. Food and Drug Administration approved IBSRELA for the treatment of irritable bowel syndrome with constipation in adults.

ShowHide Related Items >><<
ARDX Ardelyx
$6.87 /

+0.19 (+2.84%)

04/09/20 Piper Sandler
Piper has 'meaningfully higher' conviction in Ardelyx after management calls
03/09/20 Piper Sandler
Ardelyx remains a top pick after 'quiet' Q4 at Piper Sandler
02/18/20 Jefferies
Ardelyx assumed with a Buy at Jefferies
02/12/20
Fly Intel: Top five analyst initiations
Over a quarter ago
Recommendations
Piper has 'meaningfully higher' conviction in Ardelyx after management calls » 05:18
04/09/20
04/09
05:18
04/09/20
05:18
ARDX

Ardelyx

$5.70 /

+0.32 (+5.95%)

After hosting virtual…

After hosting virtual investor meetings with management this week, Piper Sandler analyst Christopher Raymond's conviction in favorite small-cap pick Ardelyx is "meaningfully higher." The stock's current valuation continues to reflect a "massive" disconnect between physician sentiment regarding tenapanor's renal opportunity and that of the Street, Raymond tells investors in a research note. When coupled with the fact that there is essentially zero COVID-19-related impact to tenapanor's timelines, or management's planned commercial preparedness activities, there is "compelling value with this name," adds the analyst. Raymond recommends buying shares of Ardelyx to levels approaching $15 and keeps an Overweight rating on the shares.

ShowHide Related Items >><<
ARDX Ardelyx
$5.70 /

+0.32 (+5.95%)

03/09/20 Piper Sandler
Ardelyx remains a top pick after 'quiet' Q4 at Piper Sandler
02/18/20 Jefferies
Ardelyx assumed with a Buy at Jefferies
02/12/20
Fly Intel: Top five analyst initiations
02/12/20 Citi
Ardelyx initiated with a Buy at Citi
Recommendations
Ardelyx remains a top pick after 'quiet' Q4 at Piper Sandler » 05:33
03/09/20
03/09
05:33
03/09/20
05:33
ARDX

Ardelyx

$6.25 /

-0.32 (-4.87%)

Piper Sandler analyst…

Piper Sandler analyst Christopher Raymond says Ardelyx remains a top pick following the company's "quiet" Q4 update. Last Friday's earnings report was uneventful, but the shares can work as investors become increasingly aware of what physicians have been saying for some time: that tenapanor is likely to be one of the biggest renal launches in history, Raymond tells investors in a research note. The analyst keeps an Overweight rating on Ardelyx with a $15 price target.

ShowHide Related Items >><<
ARDX Ardelyx
$6.25 /

-0.32 (-4.87%)

02/18/20 Jefferies
Ardelyx assumed with a Buy at Jefferies
02/12/20
Fly Intel: Top five analyst initiations
02/12/20 Citi
Ardelyx initiated with a Buy at Citi
02/10/20
Fly Intel: Top five analyst initiations

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.